Last reviewed · How we verify
continue on current dual boosted PI
continue on current dual boosted PI is a Protease inhibitor (PI) combination with pharmacokinetic booster Small molecule drug developed by Community Research Initiative of New England. It is currently FDA-approved for HIV-1 infection (as part of combination antiretroviral therapy).
Dual-boosted protease inhibitors block HIV protease to prevent viral replication and reduce viral load in HIV-infected patients.
Dual boosted PI, specifically Darunavir (DRV/r), has been studied in combination with 3TC for the treatment of HIV Infections and HBV Coinfection. This combination has been evaluated in clinical trials, such as NCT06338826, for its safety and efficacy in controlling HBV virus.
At a glance
| Generic name | continue on current dual boosted PI |
|---|---|
| Sponsor | Community Research Initiative of New England |
| Drug class | Protease inhibitor (PI) combination with pharmacokinetic booster |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Protease inhibitors (PIs) are antiretroviral drugs that inhibit HIV protease, an enzyme essential for processing viral polyproteins into functional components. Dual boosting typically involves combining a primary PI with a pharmacokinetic booster (such as ritonavir or cobicistat) to increase the primary PI's plasma concentration and half-life, improving efficacy and allowing for lower dosing. This combination is a standard component of modern antiretroviral therapy regimens for HIV management.
Approved indications
- HIV-1 infection (as part of combination antiretroviral therapy)
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
- Lipid abnormalities (elevated cholesterol and triglycerides)
- Hyperglycemia
- Lipodystrophy
- Hepatotoxicity
- Headache
Key clinical trials
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continue on current dual boosted PI CI brief — competitive landscape report
- continue on current dual boosted PI updates RSS · CI watch RSS
- Community Research Initiative of New England portfolio CI
Frequently asked questions about continue on current dual boosted PI
What is continue on current dual boosted PI?
How does continue on current dual boosted PI work?
What is continue on current dual boosted PI used for?
Who makes continue on current dual boosted PI?
What drug class is continue on current dual boosted PI in?
What development phase is continue on current dual boosted PI in?
What are the side effects of continue on current dual boosted PI?
What does continue on current dual boosted PI target?
Related
- Drug class: All Protease inhibitor (PI) combination with pharmacokinetic booster drugs
- Target: All drugs targeting HIV protease
- Manufacturer: Community Research Initiative of New England — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection (as part of combination antiretroviral therapy)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing